scPharmaceuticals Inc.
Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| scPharmaceuticals Inc | MannKind Corporation | Oct 2025 | Oct 2025 | $364 M | — | Annual report |
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2016 | $47 M | No. 4 | $10 to $50 million | equity | SEC | |
| Aug 2016 | $8 M | No. 3 | $2 to $10 million | equity | SEC | |
| Jan 2016 | $4 M | No. 2 | $2 to $10 million | debt, options | SEC | |
| Mar 2014 | $9 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
scPharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).
SEC Form D · Jan 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2017
That is all the official record says: scPharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website did not answer.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Co-Investors IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| 5AM Partners IV, LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| 5AM Ventures IV, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Dorothy Coleman | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Invest A/s Lundbeckfond | Person | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Leonard D. Schaeffer | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Sun Pharmaceutical Industries, Inc. | Company | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 15 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Abraham Ceesay | Executive officer | Jan 2017 |
| Pieter Muntendam | Executive officer | Jan 2017 |
| Troy Ignelzi | Executive officer | Jan 2017 |
| Abhay Gandhi | Director | Jan 2017 |
| Dorothy Coleman | Director | Jan 2017 |
| Jack Khattar | Director | Jan 2017 |
| Jonathan Silverstein | Director | Jan 2017 |
| Kush Parmar | Director | Jan 2017 |
| Leonard Schaeffer | Director | Jan 2017 |
| Mette Agger | Director | Jan 2017 |
| Pieter Muntendam | Director | Jan 2017 |
| Dorothy Kirstine Coleman | Director | Feb 2016 |
| Leonard Kirstine Schaeffer | Director | Feb 2016 |
| Mette Kirstine Agger | Director | Feb 2016 |
About
Company in Boston, United States.
Acquired (Oct 7, 2025). Acquired by MannKind Corporation.